Inhalation Sciences

A returning ISAB client, a mid-size US pharma company, has confirmed an IRS order worth 118,484 Euros in total following an advanced payment in February of 50,000 Euro.

The client has chosen ISAB's high-precision IPL (Isolated Perfused Lung) method to carry out the IRS project. IPL is a well-established experimental model in preclinical pharma studies for both biologics and small molecules, ISAB's version however is specially tailored and designed for aerosols generated by the company's precision dosing aerosol system PreciseInhale^®.

ISAB CEO Manoush Masarrat: "This new order reconfirms how successful our new strategic focus on Inhalation Research Services (IRS) is. Small to Medium-sized Enterprises developing inhaled drugs have an unmet need. They are looking for service providers who can deliver high-precision preclinical data that can de-risk their work from day one. We can meet that need. We look forward to starting work again with this returning US client".